The global tricuspid insufficiency treatment market is estimated to garner a large revenue by growing at a CAGR of ~18% over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the growing preference for heart surgeries with minimal invasion, rising geriatric population, and increasing demand for treating tricuspid valve regurgitation and tricuspid stenosis problems across the world. In 2017, more than 85 percent of the total robotic surgery performed in the United States were minimally invasive, out of which 71 percent surgeries were performed in hospitals. In addition to these, high preference of tricuspid insufficiency treatment in clinical trials performed by heart surgeons, is also considered to be a major factor expected to drive market growth in the upcoming years. Furthermore, prominent manufacturers in developed nations are highly emphasizing on acquisitions for expanding their regional presence and upsurging their product portfolio, which in turn is projected to offer lucrative opportunities to the market in the near future. CLICK TO DOWNLOAD SAMPLE REPORT
The market is segmented by end user into hospitals, ambulatory surgical centers, cardiac catheterization laboratories and others, out of which, the hospitals segment is anticipated to hold the largest share in the global tricuspid insufficiency treatment market on account of the increasing prevalence of open heart and minimally invasive surgeries in hospital facilities across the globe, and growing patient preference for conducting their treatment in hospitals. Along with this, on the basis of surgery type, the segment for minimally invasive surgeries is predicted to observe the highest growth over the forecast period in view of the less postoperative pain, faster recovery time, shortened hospital stay and fewer operative complications of these surgeries.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the tricuspid insufficiency treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Europe region is estimated to witness noteworthy growth over the forecast period on the back of growing adoption of tricuspid insufficiency treatment in several countries of the region, majorly in Germany. Apart from this, increasing investments to conduct research and development activities associated with cardiovascular medical devices is also expected to drive market growth in the region in the coming years. Moreover, the market in North America is evaluated to occupy the largest share during the forecast period ascribing to the rising number of cases of cardiovascular disorders and a strong presence of prominent market players in the region. As per the U.S. Centers for Disease Control and Prevention, one person in the country dies every 36 seconds from a cardiovascular disease. On an average, the calculated number of deaths from a heart disease each year are 655,000.
The global tricuspid insufficiency treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global tricuspid insufficiency treatment market includes the following segments:
FREQUENTLY ASKED QUESTIONS
The major factors driving market growth are rising preference for minimally invasive heart surgeries globally and increasing geriatric population.
The market is anticipated to attain a CAGR of ~18% over the forecast period, i.e., 2022 – 2030.
Lack of awareness about tricuspid insufficiency treatment in lower economic regions is estimated to hamper the market growth.
Europe will provide more business opportunities for market growth owing to the growing adoption of tricuspid insufficiency treatment in Germany.
The major players in the market are Abbott Laboratories, Medtronic plc, Edwards Lifesciences Corporation, LivaNova, PLC, Sorin S.p.A., and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by disease type, end user, surgery type, and by region.
The hospitals segment is anticipated to hold largest market size and is estimated to grow at a notable CAGR over the forecast period and display significant growth opportunities.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization